September 12, 2022
A New York federal judge on Monday permanently dismissed a proposed class action alleging AstraZeneca misled investors about the progress of clinical trials for its COVID-19 vaccine, finding the investors didn't identify any misleading statement from the company or show fraudulent intent.
April 30, 2021
Robbins Geller Rudman & Dowd LLP and Pomerantz LLP have been tapped to represent AstraZeneca investors in a Manhattan federal court suit alleging the company withheld information about problems in the clinical trial of its COVID-19 vaccine.
January 29, 2021
An AstraZeneca investor filed a putative class action in New York federal court Friday accusing the biopharmaceutical giant of withholding information about its COVID-19 vaccine candidate, misleading the public about the progress and adequacy of its clinical trial.